The target holds an exclusive license in U.S. & Canada for at-home and in-office rapid antigen COVID-19 test
EUA application for the COVID-19 rapid antigen test was submitted in September 2021
Target acquisition
The target holds an exclusive license in U.S. & Canada for at-home and in-office rapid antigen COVID-19 test
EUA application for the COVID-19 rapid antigen test was submitted in September 2021
Target acquisition has a range of rapid Point-of-Care diagnostics within their portfolio, including tests for celiac, and ovarian and prostate cancer
Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ:ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced it had signed a non-binding letter of intent ("LOI") to acquire a company focused on developing Point-of-Care diagnostics for early detection of diseases including cancers and SARS-CoV-2 (COVID-19) through a range of non-invasive and affordable point of care and at-home/in-office test kits.
Key strategic benefits of the proposed acquisition to Aditxt include:
- Extending AditxtScore's™ portfolio to include at-home/in-office COVID-19 rapid antigen test kits complimenting the AditxtScore™ for COVID-19, and other proprietary tests targeting Celiac, H. Pylori, and cancers including ovarian and prostate.
- Offering multiple growth opportunities focusing on the early detection of diseases.
- Access to global scale manufacturing, and clinical capabilities to support AditxtScore's commercialization efforts.
- Experienced senior management team; the current team has deep sectoral knowledge and is expected to join to support AditxtScore's next growth phase.
"The potential acquisition is complementary to AditxtScore technologically and commercially, and is one of the main components to executing our growth plans in 2022," said Amro Albanna, Co-Founder and CEO of Aditxt. "We believe that Point-of-Care rapid testing combined with our current capabilities is key to driving the transformation from reactive care to precision-driven, proactive care delivery."
The LOI is non-binding, and the closing of the transaction contemplated thereby is subject to the satisfaction of numerous conditions, including satisfactory due diligence, the negotiation, and execution of binding definitive agreements. The parties have agreed to an exclusivity period until January 31, 2022, to reach the definitive agreement. In connection with the Letter of Intent, the Company entered into a secured credit agreement with the target company, pursuant to which the Company made a secured loan to the target company in the amount of $500,000, and agreed to make additional secured loans, as requested by the target company, and approved by the Company, in an amount not to exceed $4.5 million. The loans bear interest at a rate of 8% per annum and a maturity date of December 8, 2022, provided the LOI contemplates that the loans will be forgiven upon completion of the acquisition. The consideration for the acquisition is currently expected to be comprised of cash, shares of the Company's common stock, and royalty payments on sales of the target company's products. However, there can be no assurance that the terms of a definitive agreement will be agreed to or that the proposed acquisition will be completed as proposed or at all.
Recent Comments